Literature DB >> 10995813

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

I Vergote, G J Rustin, E A Eisenhauer, G B Kristensen, E Pujade-Lauraine, M K Parmar, M Friedlander, A Jakobsen, J B Vermorken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10995813     DOI： 10.1093/jnci/92.18.1534

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  51 in total

1.  Evaluation of the clinical utility of diagnostic versus therapeutic interventions in oncology: related but quite different processes.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

2.  Treatment guidelines in ovarian cancer.

Authors:  A Poveda Velasco; A Casado Herráez; A Cervantes Ruipérez; D Gallardo Rincón; E García García; A González Martín; G López García; C Mendiola Fernández; B Ojeda González
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

3.  Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Authors:  Evelyn Despierre; Ignace Vergote; Ryan Anderson; Corneel Coens; Dionyssios Katsaros; Fred R Hirsch; Bram Boeckx; Marileila Varella-Garcia; Annamaria Ferrero; Isabelle Ray-Coquard; Els M J J Berns; Antonio Casado; Diether Lambrechts; Antonio Jimeno
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

4.  Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.

Authors:  Hong Zheng; Yu-Nong Gao
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

Review 5.  Ovarian cancer: the duplicity of CA125 measurement.

Authors:  Amer K Karam; Beth Y Karlan
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

6.  Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Authors:  Leslie M Randall; Michael W Sill; Robert A Burger; Bradley J Monk; Barbara Buening; Joel I Sorosky
Journal:  Gynecol Oncol       Date:  2011-12-01       Impact factor: 5.482

7.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; William J Hoskins; Pavani R Pingle; Mario M M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

8.  Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients.

Authors:  Vanessa L Beesley; Alexandra M Clavarino; Penelope M Webb; David K Wyld; Alessandra B Francesconi; Keith R Horwood; James D Doecke; Colleen A Loos; Adele C Green
Journal:  Support Care Cancer       Date:  2009-09-24       Impact factor: 3.603

9.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

10.  Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.

Authors:  I Ray-Coquard; B Weber; J Cretin; Z Haddad-Guichard; E Lévy; A C Hardy-Bessard; M C Gouttebel; J-F Geay; A Aleba; H Orfeuvre; C Agostini; J Provencal; J M Ferrero; D Fric; N Dohollou; D Paraiso; J Salvat; E Pujade-Lauraine
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.